# SyntheticGestalt

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syntheticgestalt

- Industry: Pharmaceuticals
- Headquarters: London, UK
- Website: https://syntheticgestalt.com
- Total disclosed funding: $4M
- Latest round: Series A (Sep 21, 2021)
- Investors on record: 3

## About

SyntheticGestalt, based in London and Japan, specializes in innovative artificial intelligence solutions that enhance drug discovery and sustainable manufacturing through advanced Geometric Deep Learning techniques.SyntheticGestalt focuses on developing AI solutions for molecular design and analysis. The company was founded by Atsuhiro Hagiwara and is currently led by CEO Koki Shimada. It has raised GBP 8 million in Series A funding from undisclosed investors, valuing the company at GBP 63 million post-money. The company's headquarters is in London, UK, with operations extending to Japan. Since its inception, SyntheticGestalt has executed three deals, with the most recent deal occurring on December 13, 2021.SyntheticGestalt specializes in the development of innovative artificial intelligence solutions aimed at the design, discovery, and analysis of small and large molecules. Their core offerings include foundation AI models that utilize advanced Geometric Deep Learning techniques, designed to predict molecular behaviors, particularly in drug discovery and enzyme applications for sustainable manufacturing. These AI models are built on extensive datasets, incorporating 3D and 4D molecular structures to enhance predictive accuracy regarding small molecule-protein interactions. The company addresses critical challenges in drug discovery, aiming to reduce the average development timeline and costs associated with new drug creation. Key clients include pharmaceutical companies and academic institutions, such as Shionogi & Co., Ltd. and Hokkaido University, with operations that extend into key markets in North America, Europe, and Asia.SyntheticGestalt generates revenue through collaborative partnerships and research agreements with pharmaceutical companies and academic institutions. The company engages in joint development projects, wherein clients leverage SyntheticGestalt's AI-powered platforms for drug discovery and enzyme identification. Revenue may be structured around project-based payments, grants, or milestone achievements in the research process. Clients benefit from specialized AI solutions tailored to their proprietary datasets, enhancing their R&D capabilities while SyntheticGestalt earns revenue through successful outcomes in discovery initiatives. The company’s flagship AI models are integral in driving these partnerships, positioning them in the biotechnology sector focused on automation and efficiency in drug and enzyme discovery processes.In December 2021, SyntheticGestalt raised GBP 8 million in Series A funding, which is part of a larger GBP 12 million round. This funding will be utilized to support the launch of new AI products aimed at enhancing drug discovery processes and enzyme identification. The company plans to expand its operations into new markets in Asia and Europe by 2023. These initiatives are expected to leverage the recent funding, facilitating further development of their AI solutions and enhancing their collaboration with existing clients.

## Funding rounds

- Series A, Sep 21, 2021, $4M — Mitsui Sumitomo Insurance Venture Capital, Incubate Fund, Future Fund

## Investors

- Mitsui Sumitomo Insurance Venture Capital (https://capitalatlas.ai/funds/mitsui-sumitomo-insurance-venture-capital) — Series A
- Incubate Fund (https://capitalatlas.ai/funds/incubate-fund) — Series A
- Future Fund — Series A